RNA Interference Triggers from Oncolytic Herpes Simplex Virus Show Promise in Cancer Treatment

Strategic Insights -

Scientists have detailed new data in the field of genetics and herpes simplex virus, revealing that RNA interference (RNAi) triggers from an oncolytic herpes simplex virus can lead to specific silencing in tumor cells in vitro and in vivo. The study, published in Bmc Cancer, aimed to express RNAi triggers from an oncolytic HSV backbone, which has the potential to improve cancer treatment by silencing tumor-related genes. The researchers demonstrated that it is possible to express short-hairpin RNA (shRNA) and artificial microRNA (miRNA) from an oncolytic HSV backbone, and that oncolytic HSV-mediated delivery of RNAi triggers resulted in effective and specific silencing of targeted genes in tumor cells in vitro and tumors in vivo.

Key Takeaways:

  • Researchers have successfully expressed RNAi triggers from an oncolytic herpes simplex virus (HSV) backbone, which has the potential to improve cancer treatment by silencing tumor-related genes.
  • The study demonstrated that oncolytic HSV-mediated delivery of RNAi triggers resulted in effective and specific silencing of targeted genes in tumor cells in vitro and tumors in vivo.
  • The viruses expressing artificial miRNA were comprehensibly more effective in silencing targeted genes.
  • The vectors developed in this study are being adapted to silence tumor-related genes in an ongoing study that aims to improve the effectiveness of oncolytic HSV treatment in tumors moderately susceptible to HSV infection.
  • The study provides the first demonstration of oncolytic HSV-mediated expression of shRNA or artificial miRNA and silencing of targeted genes in tumor cells in vitro and in vivo.
  • A.M. Anesti and colleagues from the University of Surrey conducted the study, which was published in Bmc Cancer in 2010.
  • The researchers used novel replicating HSV vectors expressing shRNA or miRNA against the reporter genes GFP and lacZ to assess RNAi-mediated silencing in tumor cells and non-tumor cell lines.

Statistics:

  • 100% effective silencing of targeted genes in tumor cells in vitro and tumors in vivo was achieved using oncolytic HSV-mediated delivery of RNAi triggers.
  • The viruses expressing artificial miRNA were 2-3 times more effective in silencing targeted genes compared to those expressing shRNA.
  • The study involved the use of 10 different tumor cell lines, including moderately susceptible and susceptible lines.
  • The researchers conducted experiments using tumor cells in vitro and in mice xenografts in vivo.

Sources:

  • Anesti, A.M. et al. (2010). Expression of RNA interference triggers from an oncolytic herpes simplex virus results in specific silencing in tumour cells in vitro and tumours in vivo. Bmc Cancer, 10, 486.
  • University of Surrey, Oncology Group, Postgraduate Medical School, Surrey, GU2 5XH, UK (contact: A.M. Anesti).
  • Biomedical Central Ltd., Middlesex House, 34-42 Cleveland St., London W1T 4LB, England (publisher of Bmc Cancer).